• DARIFENACIN CHEMBL1346 FDA Approved

    Alternate Names:

    Darifenacin
    UK-88525
    Enablex
    Xelena
    Emselex
    Darifenacin Hydrobromide Extended-release
    Apo-darifenacin
    133099-04-4
    (S)-1-(2-(2,3-dihydro-5-Benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide
    DB00496
    AC1L9FKY
    444031
    CHEBI:391960
    2-[(3S)-1-[2-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHYL]PYRROLIDIN-3-YL]-2,2-DIPHENYLACETAMIDE
    LS-187359
    CID444031
    2-{(3S)-1-[2-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHYL]PYRROLIDIN-3-YL}-2,2-DIPHENYLACETAMIDE
    AC-302
    D03654
    NCGC00168775-01
    DARIFENACIN (USAN/INN)
    MOLPORT-005-943-011
    7979027
    DAP001131
    STOCK6S-73577
    3-(S)-(-)-(1-CARBAMOYL-1,1-DIPHENYLMETHYL)-1-[2-(2,3-DIHYDROBENZOFURAN-5-YL)ETHYL]PYRROLIDINE
    3-(S)-(-)-(1-CARBAMOYL-1,1-DIPHENYLMETHYL)-1-[2-(2,3-DIHYDROBENZOFURAN-5-Y L)ETHYL]PYRROLIDINE
    2-{1-[2-(2,3-DIHYDRO-BENZOFURAN-5-YL)-ETHYL]-PYRROLIDIN-3-YL}-2,2-DIPHENYL-ACETAMIDE (DARIFENACIN)
    (S)-2-{1-[2-(2,3-DIHYDROBENZOFURAN-5-YL)ETHYL]-3-PYRROLIDINYL}-2,2-DIPHENYLACETAMIDE
    (S)-2-{1-[2-(2,3-DIHYDRO-BENZOFURAN-5-YL)-ETHYL]-PYRROLIDIN-3-YL}-2,2-DIPHENYL-ACETAMIDE
    (S)-2-(1-(2-(2,3-DIHYDROBENZOFURAN-5-YL)ETHYL)PYRROLIDIN-3-YL)-2,2-DIPHENYLACETAMIDE
    W-5196
    ST24039043
    FT-0652801
    UK 88525
    SMR002533186
    BC225565
    UK88525
    MCULE-4616748439
    CS-1168
    AKOS015907962
    BDBM50109647
    ZINC1996117
    HY-A0033
    3-PYRROLIDINEACETAMIDE, 1-(2-(2,3-DIHYDRO-5-BENZOFURANYL)ETHYL)-ALPHA,ALPHA-DIPHENYL-, (3S)-
    HXGBXQDTNZMWGS-RUZDIDTESA-N
    2-((3S)-1-(2-(2,3-DIHYDROBENZOFURAN-5-YL)ETHYL)PYRROLIDIN-3-YL)-2,2-DIPHENYLACETAMIDE
    DARIFENACIN [USAN:INN:BAN]
    MLS003876823
    GTPL321
    GTPL319
    SCHEMBL56574
    APG9819VLM
    2-[(3S)-1-[2-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHYL]PYRROLIDIN-3-YL]-2,2-DI(PHENYL)ACETAMIDE
    [3H]DARIFENACIN
    ENABLEXREG
    EMSELEXREG
    DARIFENACINUM
    DARIFENACINA
    DARIFENACIN [USAN]
    DARIFENACINE
    UNII-APG9819VLM
    AJ-32303
    135650160
    321
    135651146
    319
    SC-11779
    DARIFENACIN; 2-{1-[2-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHYL]PYRROLIDIN-3-YL}-2,2-DIPHENYLACETAMIDE; 2-{(3S)-1-[2-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHYL]PYRROLIDIN-3-YL}-2,2-DIPHENYLACETAMIDE
    2-[1-[2-(2,3-DIHYDROBENZOFURAN-5-YL)ETHYL]PYRROLIDIN-3-YL]-2,2-DIPHENYL-ACETAMIDE
    2-[1-[2-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHYL]PYRROLIDIN-3-YL]-2,2-DI(PHENYL)ACETAMIDE
    2-(1-(2-(2,3-DIHYDROBENZO[B]FURAN-5-YL)ETHYL)PYRROLIDIN-3-YL)-2,2-DIPHENYLACETAMIDE
    I14-9547
    L000215
    RT-012228
    LS-137033
    KB-220040
    AB1004893
    HE306880
    HE300384
    HE068050
    AN-15965
    AK-58009
    AKOS015917473
    STL351917
    PDSP2_000781
    PDSP1_000793
    AR-1I3470
    ANW-57645
    C28H30N2O2
    MOLPORT-009-198-962
    CTK8B7550
    CHEMBL383140
    SCHEMBL113331
    INTERMEDIATES OF DARIFENACIN
    DARIFENACIN [INN:BAN]
    AC1Q5ITE
    AC1L2HBG
    2-[1-[2-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHYL]PYRROLIDIN-3-YL]-2,2-DIPHENYLACETAMIDE
    DARFENACIN
    DARIFENICIN
    2-{1-[2-(2,3-DIHYDRO-1-BENZOFURAN-5-YL)ETHYL]PYRROLIDIN-3-YL}-2,2-DIPHENYLACETAMIDE
    2-(1-(2-(2,3-DIHYDROBENZOFURAN-5-YL)ETHYL)PYRROLIDIN-3-YL)-2,2-DIPHENYLACETAMIDE
    72054

    Drug Info:

    Drug Categories urologicals
    Drug Categories urological agents
    Drug Categories therapeutic uses
    Drug Categories physiological effects of drugs
    Drug Categories pharmacologic actions
    Drug Categories neurotransmitter agents
    Drug Categories muscarinic antagonists
    Drug Categories molecular mechanisms of pharmacological action
    Drug Categories heterocyclic compounds, 2-ring
    Drug Categories heterocyclic compounds, 1-ring
    Drug Categories heterocyclic compounds
    Drug Categories genito urinary system and sex hormones
    Drug Categories drugs for urinary frequency and incontinence
    Drug Categories cytochrome p-450 cyp3a4 substrates
    Drug Categories cytochrome p-450 cyp2d6 substrates
    Drug Categories cytochrome p-450 cyp2d6 inhibitors (moderate)
    Drug Categories cytochrome p-450 cyp2d6 inhibitors
    Drug Categories cholinergic antagonists
    Drug Categories cholinergic agents
    Drug Categories chemical actions and uses
    Drug Groups investigational
    Drug Groups approved
    Drug Type small molecule
    Year of Approval 2004
    Drug Class antispasmodics, urinary
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications for treatment of overactive bladder
    (5 More Sources)